AUTHOR=Ma Teng , Zhao Jian , Yan Yechao , Liu Junying , Zang Jie , Zhang Yaqi , Ruan Kun , Xu Hong , He Wan 

TITLE=Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1178153

DOI=10.3389/fcvm.2023.1178153

ISSN=2297-055X

ABSTRACT=Background: Osteoprotegerin (OPG) is a secretory glycoprotein and participates in the progression of atherosclerotic lesions. We aim to explore the relationship between OPG and the progression of coronary artery disease (CAD). 
Methods: OPG concentrations were measured in 3766 patients with stable CAD who were enrolled in the PEACE trial. The PEACE trial group followed them and examined future clinical events.
Results: In total, 208 (5.5%) primary outcomes occurred, 295 (7.8%) died from all-cause death, 128 (3.4%) died from cardiovascular causes and 94 (2.5%) experienced heart failure during a median follow-up of 1892 days. Higher levels of OPG were associated with higher rates of all-cause death, cardiovascular death and heart failure, even after adjusting clinical cofounders.
Conclusion: We demonstrated that elevated plasma OPG levels were associated an increased risk of all-cause death, cardiovascular death and heart failure in patients with stable CAD.